Your doctor or another healthcare professional will administer this medication. Your doctor will inform you when the next injection should be administered. It is essential that you do not miss any scheduled doses. If you cannot attend your appointment with the doctor, please make sure to call them immediately to schedule another appointment as soon as possible.
You will receive the first injection (150 mg) and the second injection (100 mg) of this medication in the upper arm approximately one week apart. From then on, you will receive an injection (between 25 mg and 150 mg) in the upper arm or buttocks once a month.
If your doctor is changing you from risperidone long-acting injectable to this medication, you will receive the first injection of this medication (between 25 mg and 150 mg) in the upper arm or buttocks at the next scheduled injection. From then on, you will receive an injection (between 25 mg and 150 mg) in the upper arm or buttocks once a month.
Your doctor may increase or decrease the amount of medication you receive at the time of the scheduled monthly injection based on your symptoms.
Patients with kidney problems
Your doctor may adjust the dose of this medication according to your renal function. If you have mild kidney problems, your doctor may give you a lower dose. You should not use this medication if you have moderate or severe kidney problems.
Patients of advanced age
Your doctor may reduce the dose of this medication if your kidney function is decreased.
If you use more BACEQ than you should
You will receive this medication under medical supervision; it is therefore unlikely that you will receive an excessive dose.
Patients who have received an excessive amount of paliperidone may experience the following symptoms: drowsiness or sedation, rapid heart rate, low blood pressure, electrocardiogram abnormalities (heart tracing), or slow or abnormal movements of the face, body, arms, or legs.
If you interrupt treatment with BACEQ
If you stop receiving your injections, the effects of the medication will be lost. Do not stop using this medication unless your doctor tells you to, as your symptoms may return.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Inform your doctor immediately if:
The following side effects may occur:
Very common side effects: can affect more than 1 in 10 patients
Common side effects: can affect up to 1 in 10 patients
Rare side effects: can affect up to 1 in 100 patients
Rare side effects: can affect up to 1 in 1,000 patients
Unknown frequency: cannot be estimated from available data
Reporting of side effects
If you experience any type of side effect, consult your doctor or nurse, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System of Pharmacovigilance of Medicines for Human Use:https://www.notificaRAM.es.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the pre-filled syringe and on the box after “CAD or EXP”. The expiration date is the last day of the month indicated.
This medication does not require any special storage conditions.
Medications should not be disposed of through drains or in the trash. Dispose of the containers and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medications you no longer need. By doing so, you will help protect the environment.
Composition of BACEQ
The active ingredient is paliperidone
Each BACEQ 25 mg pre-filled syringe contains 39 mg of palmitate of paliperidone in 0.25 ml.
Each BACEQ 50 mg pre-filled syringe contains 78 mg of palmitate of paliperidone in 0.5 ml.
Each BACEQ 75 mg pre-filled syringe contains 117 mg of palmitate of paliperidone in 0.75 ml.
Each BACEQ 100 mg pre-filled syringe contains 156 mg of palmitate of paliperidone in 1 ml.
Each BACEQ 150 mg pre-filled syringe contains 234 mg of palmitate of paliperidone in 1.5 ml
Starting treatment package:
Each BACEQ 100 mg pre-filled syringe contains 156 mg of palmitate of paliperidone in 1 ml.
Each BACEQ 150 mg pre-filled syringe contains 234 mg of palmitate of paliperidone in 1.5 ml
The other components are:
polysorbate 20
macrogol 4000
monohydrate citric acid
disodium phosphate
dihydrogen phosphate of sodium monohydrate
sodium hydroxide (for pH adjustment)
water for injection
Appearance of the product and contents of the package
BACEQ is a white to off-white prolonged-release injectable suspension, which comes in a pre-filled syringe (prolonged-release injectable)
Each package contains 1 pre-filled syringe and 2 needles.
Starting treatment package:
Each package contains 1 BACEQ 150 mg package and 1 BACEQ 100 mg package.
Only some package sizes may be marketed.
Marketing authorization holder and manufacturer responsible
Marketing authorization holder
Teva Pharma, S.L.U.
C/ Anabel Segura, 11, Edificio Albatros B, 1st floor,
Alcobendas, 28108, Madrid (Spain)
Manufacturer responsible:
Actavis Group PTC ehf.
Dalsharun 1
IS-220 Hafnarfjordur
Iceland
For more information about this medicine, please contact the local representative of the marketing authorization holder:
Laboratorios Farmacéuticos ROVI, S.A.
Julián Camarillo, 35
28037 – Madrid – Spain
This medicine is authorized in the Member States of the European Economic Area with the following names:
|
Last review date of this leaflet:February 2024
More detailed information about this medicine is available on the website of theSpanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es
This information is intended only for doctors or healthcare professionals and should be read together with the complete prescribing information (Summary of Product Characteristics).
The injectable suspension is for single use. It should be visually inspected to detect any foreign particles before administration. Do not use the product if the syringe is not visually free of foreign particles.
The package contains a pre-filled syringe and two safety needles (one 22 gauge 1½ inch [38.1 mm x 0.72 mm] needle with a blue shaft and one 23 gauge 1 inch [25.4 mm x 0.64 mm] needle with a grey shaft) for intramuscular injection. BACEQ is also available in a treatment initiation pack containing two pre-filled syringes (150 mg + 100 mg) and two additional safety needles.
The first dose of BACEQ (150 mg) is administered on Day 1 in the deltoid muscle using the deltoid muscle injection needle. The second dose of BACEQ (100 mg) is administered also in the deltoid muscle one week later (Day 8) using the deltoid muscle injection needle.
If the patient is switched from risperidone prolonged-release injectable to BACEQ, the first BACEQ injection (dose range 25 mg to 150 mg) can be administered in the deltoid muscle or gluteus muscle using the appropriate needle for the injection site at the time of the next scheduled injection.
Subsequent monthly maintenance injections can be administered in both the deltoid muscle and gluteus muscle using the appropriate needle for the injection site.
For deltoid muscle injection, if the patient weighs <90>23kg, use the 23 gauge 1 inch [25.4 mm x 0.64 mm] needle (needle with a blue shaft); if the patient weighs?90 kg, use the 22 gauge 1½ inch [38.1 mm x 0.72 mm] needle (needle with a grey shaft).
For gluteus muscle injection, use the 22 gauge 1½ inch [38.1 mm x 0.72 mm] needle (needle with a grey shaft).
8a
8b
8c
The disposal of unused medication and all materials that have come into contact with it will be carried out in accordance with local regulations.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.